Development and validation of plasma miRNA biomarker signature panel for the detection of early HIV-1 infection.
Acute HIV-1
Early HIV-1
Plasma miRNA and circulatory biomarker
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
15
02
2019
revised:
27
03
2019
accepted:
09
04
2019
pubmed:
22
4
2019
medline:
26
11
2019
entrez:
22
4
2019
Statut:
ppublish
Résumé
Accurate laboratory diagnosis of HIV is essential to reduce the risk of HIV-positive individuals transmitting HIV-1 infection. The goal of this study was to identify and assess a panel of host derived plasma miRNAs that could to serve as a prognostic and predictive biomarker to detect early/acute HIV-1 infection. A total of 372 microRNAs were analyzed in nine plasma samples from HIV-1 infected individuals in the early phase of infection and three healthy controls using the miRNA PCR-array. Seventeen microRNAs were selected and validated in 80 plasma samples from HIV-1 infected individuals in the early phase of infection (20 each of eclipse stage, RNA+ stage, Ag + stage, and Ag + Ab+ stage of HIV-1 patients) and 25 healthy controls. Using the validation study results a plasma miRNA panel was developed and evaluated to detect early/acute HIV-1 infection in 49 blinded samples. We identified an miRNA panel (P The miRNA panel, P
Sections du résumé
BACKGROUND
BACKGROUND
Accurate laboratory diagnosis of HIV is essential to reduce the risk of HIV-positive individuals transmitting HIV-1 infection. The goal of this study was to identify and assess a panel of host derived plasma miRNAs that could to serve as a prognostic and predictive biomarker to detect early/acute HIV-1 infection.
METHODS
METHODS
A total of 372 microRNAs were analyzed in nine plasma samples from HIV-1 infected individuals in the early phase of infection and three healthy controls using the miRNA PCR-array. Seventeen microRNAs were selected and validated in 80 plasma samples from HIV-1 infected individuals in the early phase of infection (20 each of eclipse stage, RNA+ stage, Ag + stage, and Ag + Ab+ stage of HIV-1 patients) and 25 healthy controls. Using the validation study results a plasma miRNA panel was developed and evaluated to detect early/acute HIV-1 infection in 49 blinded samples.
FINDING
RESULTS
We identified an miRNA panel (P
INTERPRETATION
CONCLUSIONS
The miRNA panel, P
Identifiants
pubmed: 31005516
pii: S2352-3964(19)30262-2
doi: 10.1016/j.ebiom.2019.04.023
pmc: PMC6557912
pii:
doi:
Substances chimiques
Biomarkers
0
Circulating MicroRNA
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
307-316Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019. Published by Elsevier B.V.
Références
AIDS. 2000 Oct 20;14(15):2283-91
pubmed: 11089616
AIDS. 2000 Oct 20;14(15):2333-9
pubmed: 11089621
AIDS. 2003 Sep 5;17(13):1871-9
pubmed: 12960819
J Infect Dis. 2004 May 15;189(10):1785-92
pubmed: 15122514
J Infect Dis. 2005 May 1;191(9):1403-9
pubmed: 15809897
J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):133-7
pubmed: 15905727
J Infect Dis. 2007 Apr 1;195(7):951-9
pubmed: 17330784
Acta Paediatr. 2007 May;96(5):644-7
pubmed: 17376185
J Clin Microbiol. 2008 May;46(5):1588-95
pubmed: 18322061
PLoS Med. 2008 Mar 18;5(3):e50
pubmed: 18351795
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7
pubmed: 18490657
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Cell Res. 2008 Oct;18(10):997-1006
pubmed: 18766170
J Virol. 2008 Dec;82(24):12449-63
pubmed: 18842730
J Theor Biol. 2009 Nov 21;261(2):341-60
pubmed: 19660475
Gut. 2010 Jul;59(7):1002-4; author reply 1004
pubmed: 20581247
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
Crit Rev Oncol Hematol. 2011 Nov;80(2):193-208
pubmed: 21145252
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8
pubmed: 21383194
Lancet. 2011 Jul 16;378(9787):256-68
pubmed: 21684591
J Clin Virol. 2011 Dec;52 Suppl 1:S17-22
pubmed: 21981983
Circ Res. 2012 Feb 3;110(3):483-95
pubmed: 22302755
Med Res Rev. 2012 Mar;32(2):326-48
pubmed: 22383180
Curr HIV/AIDS Rep. 2012 Jun;9(2):101-10
pubmed: 22415472
PLoS One. 2012;7(3):e33948
pubmed: 22479485
Am J Respir Crit Care Med. 2012 Dec 1;186(11):1160-7
pubmed: 23043084
BMC Infect Dis. 2012 Dec 28;12:384
pubmed: 23272999
J Clin Invest. 2013 Jan;123(1):11-8
pubmed: 23281405
N Engl J Med. 2013 Jan 17;368(3):218-30
pubmed: 23323898
Transfusion. 2013 Oct;53(10 Pt 2):2384-98
pubmed: 23445273
Blood. 2013 Jun 20;121(25):4977-84
pubmed: 23550041
Lancet. 2013 Nov 2;382(9903):1515-24
pubmed: 24152938
J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):229-37
pubmed: 24675587
Viruses. 2014 Apr 02;6(4):1525-39
pubmed: 24699363
Sci Rep. 2014 Aug 01;4:5915
pubmed: 25081906
Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13475-80
pubmed: 25097264
J Clin Virol. 2014 Dec;61(4):623-4
pubmed: 25453336
Int J Med Sci. 2016 Feb 18;13(3):195-205
pubmed: 26941580
Sci Rep. 2016 Apr 21;6:24496
pubmed: 27098369
Clin Infect Dis. 2016 Aug 1;63(3):425-6
pubmed: 27143670
Viruses. 2016 May 02;8(5):
pubmed: 27144577
JAMA. 1997 Jul 2;278(1):58-62
pubmed: 9207340